{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:03:51Z","timestamp":1789632231883,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82471110"],"award-info":[{"award-number":["82471110"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Photodiagnosis and Photodynamic Therapy"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.pdpdt.2026.105415","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T08:13:48Z","timestamp":1772093628000},"page":"105415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Long-term outcomes of 3+PRN versus 5+PRN anti-VEGF regimens for ischemic and non-ischemic central retinal vein occlusion-associated macular edema"],"prefix":"10.1016","volume":"58","author":[{"given":"Ya","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Meng","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Ying","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Ping","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pdpdt.2026.105415_bib0001","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00417-020-04932-0","article-title":"Macular edema secondary to retinal vein occlusion in a real-life setting: a multicenter, nationwide, 3-year follow-up study","volume":"259","author":"Costa","year":"2021","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.pdpdt.2026.105415_bib0002","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000502041","article-title":"Guidelines for the management of retinal vein occlusion by the European society of retina specialists (EURETINA)","volume":"242","author":"Schmidt-Erfurth","year":"2019","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.pdpdt.2026.105415_bib0003","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.ophtha.2012.01.042","article-title":"Vascular endothelial growth factor trap-eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study","volume":"119","author":"Boyer","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.pdpdt.2026.105415_bib0004","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/bjophthalmol-2012-301504","article-title":"VEGF trap-eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study","volume":"97","author":"Holz","year":"2013","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.pdpdt.2026.105415_bib0005","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1001\/jama.2017.4568","article-title":"Effect of bevacizumab vs aflibercept on visual acuity among patients with macular edema due to central retinal vein occlusion: the SCORE2 randomized clinical trial","volume":"317","author":"Scott","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.pdpdt.2026.105415_bib0006","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","article-title":"Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study","volume":"117","author":"Brown","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.pdpdt.2026.105415_bib0007","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1001\/jamaophthalmol.2019.3305","article-title":"Clinical effectiveness of intravitreal therapy with ranibizumab vs aflibercept vs bevacizumab for macular edema secondary to central retinal vein occlusion: a randomized clinical trial","volume":"137","author":"Hykin","year":"2019","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.pdpdt.2026.105415_bib0008","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s41433-020-0827-y","article-title":"One-year efficacy of intravitreal conbercept injection for macular oedema secondary to central retinal vein occlusion in Chinese patients","volume":"34","author":"Zeng","year":"2020","journal-title":"Eye"},{"key":"10.1016\/j.pdpdt.2026.105415_bib0009","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.sjopt.2017.09.009","article-title":"Aflibercept in macular edema secondary to retinal vein occlusion: a real life study","volume":"31","author":"Ozkaya","year":"2017","journal-title":"Saudi J. Ophthalmol."},{"key":"10.1016\/j.pdpdt.2026.105415_bib0010","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/IAE.0000000000001579","article-title":"Ranibizumab for retinal vein occlusion: predictive factors and long-term outcomes in real-life data","volume":"38","author":"Chatziralli","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.pdpdt.2026.105415_bib0011","first-page":"1","article-title":"Changes of diagnosis and treatment strategies of retinal vein occlusion according to EURETINA updated guidelines","volume":"21","author":"Dai","year":"2020","journal-title":"Chin. J. Exp. Ophthalmol."},{"key":"10.1016\/j.pdpdt.2026.105415_bib0012","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1159\/000530294","article-title":"Real-world outcomes of Ranibizumab treatment in French patients with visual impairment due to macular edema secondary to retinal vein occlusion: 24-month results from the BOREAL-RVO study","volume":"66","author":"Glacet-Bernard","year":"2023","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.pdpdt.2026.105415_bib0013","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/ceo.13636","article-title":"Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab","volume":"48","author":"Spooner","year":"2020","journal-title":"Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.pdpdt.2026.105415_bib0014","first-page":"175","volume":"40","year":"2024","journal-title":"Chin. J. Ocul. Fundus Dis."},{"key":"10.1016\/j.pdpdt.2026.105415_bib0015","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/09273948.2019.1681474","article-title":"Comparison of Ranibizumab versus aflibercept in treating macular edema among patients with serous retinal detachment secondary to branch retinal vein occlusion","volume":"29","author":"Kucuk","year":"2021","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.pdpdt.2026.105415_bib0016","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3928\/23258160-20230320-01","article-title":"Meta-analyses of two treatment regimens for retinal vein occlusion","volume":"54","author":"Snider","year":"2023","journal-title":"Ophthal. Surg. Lasers Imag. Ret."},{"key":"10.1016\/j.pdpdt.2026.105415_bib0017","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/IAE.0000000000001224","article-title":"Ranibizumab for macular edema after branch retinal vein occlusion: one initial injection versus three monthly injections","volume":"37","author":"Miwa","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.pdpdt.2026.105415_bib0018","first-page":"830","article-title":"Retinal vascular occlusion: modern therapeutic approaches","volume":"235","author":"Pettenkofer","year":"2018","journal-title":"Klin Monbl Augenheilkd"},{"issue":"5","key":"10.1016\/j.pdpdt.2026.105415_bib0019","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.ophtha.2016.01.011","article-title":"Individualized Ranibizumab regimen driven by stabilization criteria for central retinal vein occlusion: twelve-month results of the CRYSTAL study","volume":"123","author":"Larsen","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.pdpdt.2026.105415_bib0020","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1080\/17512433.2018.1507735","article-title":"Comparative efficacy of bevacizumab, ranibizumab, and aflibercept for treatment of macular edema secondary to retinal vein occlusion: a systematic review and network meta-analysis","volume":"11","author":"Sangroongruangsri","year":"2018","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.pdpdt.2026.105415_bib0021","doi-asserted-by":"crossref","first-page":"97","DOI":"10.5935\/0004-2749.20170024","article-title":"Incidence of anterior segment neovascularization during intravitreal treatment for macular edema secondary to central retinal vein occlusion","volume":"80","author":"Lucatto","year":"2017","journal-title":"Arq. Bras. Oftalmol."},{"key":"10.1016\/j.pdpdt.2026.105415_bib0022","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ophtha.2013.08.012","article-title":"Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study","volume":"121","author":"Korobelnik","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.pdpdt.2026.105415_bib0023","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.ophtha.2014.01.027","article-title":"Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study","volume":"121","author":"Heier","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.pdpdt.2026.105415_bib0024","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ajo.2012.09.026","article-title":"Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study","volume":"155","author":"Brown","year":"2013","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.pdpdt.2026.105415_bib0025","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/bjophthalmol-2014-306543","article-title":"A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report No. 1","volume":"99","author":"Narayanan","year":"2015","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.pdpdt.2026.105415_bib0026","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.4103\/ijo.IJO_1330_22","article-title":"Long-term real-world outcomes in retinal vein occlusions: how close are we to the trials?","volume":"70","author":"Shah","year":"2022","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.pdpdt.2026.105415_bib0027","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/s41433-021-01620-z","article-title":"Long-term outcomes of anti-VEGF treatment of retinal vein occlusion","volume":"36","author":"Spooner","year":"2022","journal-title":"Eye"},{"key":"10.1016\/j.pdpdt.2026.105415_bib0028","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1007\/s00417-021-05146-8","article-title":"Real-life study of the use of anti-VEGF therapy versus dexamethasone implant for treatment of macular edema in retinal vein occlusion","volume":"259","author":"de Salles","year":"2021","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.pdpdt.2026.105415_bib0029","first-page":"431","article-title":"Comparison of anti-vascular endothelial growth factors, laser treatments and a combination of the both for treatment of central retinal vein occlusion","volume":"9","author":"Pikkel","year":"2016","journal-title":"Int. J. Ophthalmol."},{"key":"10.1016\/j.pdpdt.2026.105415_bib0030","first-page":"1563","article-title":"Clinical efficacy evaluation of treatment of different degrees of retinal vein occlusion with ranibizumab combined with an argon ion laser","volume":"17","author":"Wang","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.pdpdt.2026.105415_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2021.100964","article-title":"Photocoagulation for retinal vein occlusion","volume":"85","author":"Hayreh","year":"2021","journal-title":"Prog. Retin. Eye Res."},{"issue":"3","key":"10.1016\/j.pdpdt.2026.105415_bib0032","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1442-9071.2008.01723.x","article-title":"Verteporfin photodynamic therapy for anterior segment neovascularization secondary to ischaemic central retinal vein occlusion","volume":"36","author":"Parodi","year":"2008","journal-title":"Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.pdpdt.2026.105415_bib0033","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/aos.14118","article-title":"Optos wide-field imaging versus conventional camera imaging in Danish patients with type 2 diabetes","volume":"97","author":"Byberg","year":"2019","journal-title":"Acta Ophthalmol."}],"container-title":["Photodiagnosis and Photodynamic Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1572100026000827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1572100026000827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:19:29Z","timestamp":1789629569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1572100026000827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":33,"alternative-id":["S1572100026000827"],"URL":"https:\/\/doi.org\/10.1016\/j.pdpdt.2026.105415","relation":{},"ISSN":["1572-1000"],"issn-type":[{"value":"1572-1000","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term outcomes of 3+PRN versus 5+PRN anti-VEGF regimens for ischemic and non-ischemic central retinal vein occlusion-associated macular edema","name":"articletitle","label":"Article Title"},{"value":"Photodiagnosis and Photodynamic Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pdpdt.2026.105415","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105415"}}